CA3232521A1 - Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof - Google Patents

Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof Download PDF

Info

Publication number
CA3232521A1
CA3232521A1 CA3232521A CA3232521A CA3232521A1 CA 3232521 A1 CA3232521 A1 CA 3232521A1 CA 3232521 A CA3232521 A CA 3232521A CA 3232521 A CA3232521 A CA 3232521A CA 3232521 A1 CA3232521 A1 CA 3232521A1
Authority
CA
Canada
Prior art keywords
liver
mannitol
combination
group
sucralose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232521A
Other languages
English (en)
French (fr)
Inventor
Oliver Yoa-Pu Hu
Tung-Yuan SHIH
Cheng-Huei Hsiong
Hsin-Tien HO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinew Pharma Inc
Original Assignee
Sinew Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/078039 external-priority patent/WO2017084234A1/zh
Application filed by Sinew Pharma Inc filed Critical Sinew Pharma Inc
Publication of CA3232521A1 publication Critical patent/CA3232521A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/215—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of saturated hydrocarbyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/42—Glutaric acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3232521A 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof Pending CA3232521A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562222959P 2015-09-24 2015-09-24
US62/222,959 2015-09-24
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
CNPCT/CN2016/078039 2016-03-31
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物
CA2999368A CA2999368C (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2999368A Division CA2999368C (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Publications (1)

Publication Number Publication Date
CA3232521A1 true CA3232521A1 (en) 2017-03-30

Family

ID=60047309

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3232521A Pending CA3232521A1 (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CA2999368A Active CA2999368C (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2999368A Active CA2999368C (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Country Status (20)

Country Link
US (4) US10456371B2 (enExample)
EP (3) EP4609911A3 (enExample)
JP (2) JP2018537517A (enExample)
KR (2) KR102891137B1 (enExample)
CN (4) CN120349362A (enExample)
AU (3) AU2016327930B2 (enExample)
BR (1) BR112018005905B1 (enExample)
CA (2) CA3232521A1 (enExample)
EA (1) EA201890810A1 (enExample)
ES (1) ES3044383T3 (enExample)
HK (1) HK1244266A1 (enExample)
HR (1) HRP20250899T1 (enExample)
HU (1) HUE072982T2 (enExample)
MX (2) MX395231B (enExample)
MY (1) MY190647A (enExample)
PH (1) PH12018500659A1 (enExample)
SG (1) SG10202002573RA (enExample)
TW (1) TWI781912B (enExample)
WO (1) WO2017050298A1 (enExample)
ZA (1) ZA201802373B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2929945T3 (es) * 2013-11-13 2022-12-05 National Defense Education And Res Foundation Nueva composición de un compuesto de acetaminofeno sin efectos secundarios sobre el hígado
EP4609911A3 (en) 2015-09-24 2025-11-19 Sinew Pharma Inc. Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CN107613968A (zh) * 2015-11-19 2018-01-19 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
JP2021513548A (ja) * 2018-02-14 2021-05-27 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． アセトアミノフェン（ａｐａｐ）によって引き起こされる毒性を予防、低減または根絶するための方法および組成物
CN110538187A (zh) * 2018-05-28 2019-12-06 北京大学 Cpt1激活剂
KR102136326B1 (ko) * 2018-09-06 2020-07-22 서울대학교산학협력단 가시박으로부터 분리한 플라보노이드 유도체를 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
WO2020152122A1 (en) * 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
CN110269855A (zh) * 2019-07-19 2019-09-24 辽宁大学 黄酮类小分子化合物在制备抑制胰脂肪酶活性药物中的应用
US12383191B1 (en) * 2020-05-04 2025-08-12 PathAI, Inc. Systems and methods for assessing liver pathology
CN113999272A (zh) * 2021-10-29 2022-02-01 广西医科大学 香蜂草苷的制备方法及其应用
CN113875982A (zh) * 2021-11-19 2022-01-04 武汉森澜生物科技有限公司 一种含二氢杨梅素的抗衰组合物及其应用
CN117482082A (zh) * 2023-11-27 2024-02-02 西北大学 金松双黄酮在制备抗慢性肾损伤药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661519A (en) * 1983-04-12 1987-04-28 Pola Chemical Industries Inc. Method for dermatological application
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JP3916685B2 (ja) * 1996-02-29 2007-05-16 第一製薬株式会社 ガラクトース誘導体
JP4677550B2 (ja) * 2002-08-14 2011-04-27 独立行政法人産業技術総合研究所 環状エステル化合物
TWI287990B (en) * 2004-01-08 2007-10-11 Nat Defense Medical Ct Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B)
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN1939929A (zh) * 2005-09-29 2007-04-04 云南白药集团股份有限公司 一种偏诺皂苷类化合物酸式盐及制备方法
WO2012142724A1 (zh) * 2011-04-20 2012-10-26 国防教育研究基金会 无/低副作用的抗结核病药物复方
CN104937007A (zh) * 2012-11-12 2015-09-23 赛格提斯公司 可交联聚缩酮酯、其制造方法和用途
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
CN105143428B (zh) * 2013-04-29 2017-08-25 哈沙·奇古鲁帕蒂 酒精饮料中降低的毒性
TWI552748B (zh) 2013-10-25 2016-10-11 The use of a compound for the removal of hepatotoxicity against Acetaminophen (APAP)
CN104623670A (zh) * 2013-11-06 2015-05-20 高松 一种含西红花素的组合物及其应用
ES2929945T3 (es) * 2013-11-13 2022-12-05 National Defense Education And Res Foundation Nueva composición de un compuesto de acetaminofeno sin efectos secundarios sobre el hígado
CN104292289B (zh) * 2014-07-10 2017-12-29 程怡 半乳糖配体及其在肝靶向脂质体中的应用
EP4609911A3 (en) * 2015-09-24 2025-11-19 Sinew Pharma Inc. Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CN107613968A (zh) * 2015-11-19 2018-01-19 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物

Also Published As

Publication number Publication date
MY190647A (en) 2022-04-30
SG10202002573RA (en) 2020-05-28
EP3991724A2 (en) 2022-05-04
EA201890810A1 (ru) 2018-11-30
EP3353144A1 (en) 2018-08-01
AU2021205040A1 (en) 2021-08-12
US20220265587A1 (en) 2022-08-25
EP3991724C0 (en) 2025-07-16
US20200009097A1 (en) 2020-01-09
BR112018005905B1 (pt) 2023-03-21
CN122080093A (zh) 2026-05-26
JP2022009680A (ja) 2022-01-14
CN107614475A (zh) 2018-01-19
MX2022007816A (es) 2022-08-02
US20240335404A1 (en) 2024-10-10
KR20240042148A (ko) 2024-04-01
JP2018537517A (ja) 2018-12-20
AU2016327930A1 (en) 2018-05-10
MX395231B (es) 2025-03-25
KR102891137B1 (ko) 2025-11-25
HUE072982T2 (hu) 2025-12-28
CA2999368C (en) 2026-07-21
US11285123B2 (en) 2022-03-29
JP7261850B2 (ja) 2023-04-20
BR112018005905A2 (pt) 2018-10-16
CN120398980A (zh) 2025-08-01
AU2021205040B2 (en) 2023-11-16
EP3991724A3 (en) 2022-07-27
MX2018003700A (es) 2018-08-01
AU2024200963B2 (en) 2026-02-12
US12083088B2 (en) 2024-09-10
EP4609911A3 (en) 2025-11-19
AU2024200963A1 (en) 2024-03-07
HRP20250899T1 (hr) 2025-11-07
ZA201802373B (en) 2019-04-24
CN120349362A (zh) 2025-07-22
US10456371B2 (en) 2019-10-29
EP3991724B1 (en) 2025-07-16
AU2016327930B2 (en) 2021-04-15
TWI781912B (zh) 2022-11-01
US20180256526A1 (en) 2018-09-13
EP3353144A4 (en) 2019-06-05
PH12018500659A1 (en) 2018-10-01
KR20180058795A (ko) 2018-06-01
ES3044383T3 (en) 2025-11-26
HK1244266A1 (zh) 2018-08-03
EP4609911A2 (en) 2025-09-03
TW201722897A (zh) 2017-07-01
WO2017050298A1 (en) 2017-03-30
CA2999368A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
US12083088B2 (en) Substituted esters containing polyols and saccharides for treating hepatotoxicity and fatty liver diseases
Wang et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti‐HIV activity
Yamamoto et al. Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3′-O-glucuronide, exerts hypotensive, vasodilatory, and anti-inflammatory activities
Nie et al. Discovery and anti-diabetic effects of novel isoxazole based flavonoid derivatives
US10765660B2 (en) Agent containing flavonoid derivatives for treating cancer and inflammation
WO2015019193A2 (en) Acylated derivatives of phloridzin and isoquercetrin as anticancer therapeutics and methods of use thereof
HK40131488A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
US20020091093A1 (en) Anti-inflammatory compounds derived from Pseudopterogorgia elisabethae
HK40129564A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
HK40128564A (zh) 有效於治疗肝毒性及脂肪肝疾病的化合物及其用途
EA040650B1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN114478464B (zh) 一种炎症小体选择性抑制剂及其合成方法和应用
Barron Recent advances in the chemical synthesis and biological activity of phenolic metabolites
Supriya et al. Anti-bacterial, anti-fungal and analgesic activity of papain conjugated quercetin
JP2021017420A (ja) 脳由来神経栄養因子産生促進剤、神経成長因子産生促進剤、酸化ストレス抑制剤及びそれらの使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240319

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - SMALL

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240724

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250313

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250710

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - SMALL

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - SMALL

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260722